The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) (ATHENA-SSc-ILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05270668
Recruitment Status : Recruiting
First Posted : March 8, 2022
Last Update Posted : May 7, 2024
Information provided by (Responsible Party):
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 19, 2025
Estimated Study Completion Date : December 30, 2028